Increased basal ganglia binding of18F-AV-1451 in patients with progressive supranuclear palsy

In vivoimaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET

(2016) Allan K. Hansen et al.   BRAIN

An autoradiographic evaluation of AV-1451 Tau PET in dementia

(2016) Val J. Lowe et al.   Acta Neuropathologica Communications

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue

(2015) Marta Marquié et al.   ANNALS OF NEUROLOGY

The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases

(2014) Gesine Respondek et al.   MOVEMENT DISORDERS

Evaluation of Two Automated Methods for PET Region of Interest Analysis

(2014) Martin Schain et al.   NEUROINFORMATICS

Variation in tau isoform expression in different brain regions and disease states

(2013) Elisa Majounie et al.   NEUROBIOLOGY OF AGING

Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls

(2013) Masahiro Maruyama et al.   NEURON

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

(2012) Sara Hall et al.   ARCHIVES OF NEUROLOGY

Movement disorders: role of imaging in diagnosis

(2012) Mario Mascalchi et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: Determining sample size for treatment trials

(2011) Jennifer L. Whitwell et al.   PARKINSONISM & RELATED DISORDERS

Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges

(2009) David R Williams et al.   LANCET NEUROLOGY

Cerebellar involvement in progressive supranuclear palsy: A clinicopathological study

(2009) Masato Kanazawa et al.   MOVEMENT DISORDERS